Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. IBio, Inc.
  6. Summary
    IBIO   US4510332038

IBIO, INC.

(IBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/15/2021 10/18/2021 10/19/2021 10/20/2021 10/21/2021 Date
0.9(c) 0.8725(c) 0.8963(c) 0.8761(c) 0.8534(c) Last
2 798 280 2 106 253 1 715 433 1 736 756 2 167 053 Volume
+2.79% -3.06% +2.73% -2.25% -2.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 4,00 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 10,0 M - -
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 186 M 186 M -
Capi. / Sales 2022 46,5x
Capi. / Sales 2023 18,6x
Nbr of Employees 62
Free-Float 99,0%
More Financials
Company
iBio, Inc. is a developer of biopharmaceuticals and FastPharming Manufacturing System. The Company is applying its technologies to develop product candidates to treat or prevent fibrotic diseases, cancers, and infectious diseases. The Company is using its FastPharming Manufacturing System (FastPharming System) and Glycaneering Services to build a portfolio of biologic drug candidates. The Company is also using the... 
Sector
Pharmaceuticals
Calendar
11/22Earnings Release
More about the company
All news about IBIO, INC.
09/28IBIO : Management's Discussion and Analysis of Financial Condition and Results of Operatio..
AQ
09/27IBIO : Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporat..
PU
09/27IBIO, INC. : Results of Operations and Financial Condition, Financial Statements and Exhib..
AQ
09/27IBio, Inc. Provides Revenue Guidance for the First Half, Second Half and Full Year of F..
CI
09/27IBIO : Earnings Flash (IBIO) IBIO Reports Q4 Revenue $0.5M
MT
09/27iBio Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corpora..
GL
09/27Ibio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2021
CI
09/27NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
09/20IBIO : to Participate in the Cantor 2021 Virtual Global Healthcare Conference
AQ
09/20iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide C..
GL
09/07iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conferenc..
GL
08/31IBIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08/31Seymour Flug Resigns as Director of iBio, Inc
CI
08/30IBIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
08/27IBIO : THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RUBRYC THERAPEUTICS, INC..
PU
More news
News in other languages on IBIO, INC.
09/27IBio, Inc. fournit des prévisions de revenus pour le premier semestre, le second semest..
09/27Earnings Flash (IBIO) IBIO annonce un chiffre d'affaires de 0,5 million de dollars pour..
2020IBM : une plateforme d'essais cliniques contre le Covid
More news
Analyst Recommendations on IBIO, INC.
More recommendations
Chart IBIO, INC.
Duration : Period :
iBio, Inc. Technical Analysis Chart | IBIO | US4510332038 | MarketScreener
Technical analysis trends IBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,85 $
Average target price 3,00 $
Spread / Average Target 252%
Managers and Directors
Thomas F. Isett Chairman & Chief Executive Officer
Robert M. Lutz Chief Financial & Business Officer
Martin B. Brenner Chief Scientific Officer
Randy J. Maddux Chief Operating Officer
Glenn J. Chang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IBIO, INC.-18.72%186
JOHNSON & JOHNSON3.83%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.16.27%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY42.84%220 952